Ketazocine
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | 36292-69-0 Y |
PubChem (CID) | 3054741 |
ChemSpider | 2316328 Y |
UNII | 6IO4IG518S Y |
KEGG | D04649 Y |
Chemical and physical data | |
Formula | C18H23NO2 |
Molar mass | 285.38 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Ketazocine (INN), also known as ketocyclazocine, is a benzomorphan derivative used in opioid receptor research. Ketocyclazocine is an exogenous opioid that binds to the κ opioid receptor.[1]
Activation of this receptor is known to cause sleepiness, a decrease in pain sensation and (potentially) dysphoria, paranoia, and hallucinations. It also causes an increase in urine production because it inhibits the release of vasopressin. (Vasopressin is an endogenous substance that assists in regulating fluid and electrolyte balance in the body and decreases the amount of water released into the urine.)
Unlike other opioids, substances that only bind to the κ receptor theoretically do not depress the respiratory system.
See also
References
- ↑ Leander JD (Sep 1982). "Effects of ketazocine, ethylketazocine and phenazocine on schedule-controlled behavior: antagonism by naloxone". Neuropharmacology. 21 (9): 923–8. doi:10.1016/0028-3908(82)90085-5. PMID 6128693.
MOR |
|
---|---|
DOR |
|
KOR |
|
NOP |
|
Unsorted |
|
Others |
|
See also: Peptide receptor modulators |
This article is issued from Wikipedia - version of the 4/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.